New antibody takes on Hard-to-Treat myeloma
NCT ID NCT06381141
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a drug called CLN-619 in 30 people with multiple myeloma that has come back or stopped responding to treatment. CLN-619 is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLN-619 (an antibody that targets MICA/MICB proteins on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1b) and small (30 people) study focused mainly on safety. It may not show enough benefit or could have side effects that limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Levine Cancer Institute
Winston-Salem, North Carolina, 27157, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering (MSK)
New York, New York, 10065, United States
-
Mt. Sinai
New York, New York, 10029, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States